As well as the relatively low mutation burden in pancreatic cancer, that in itself makes pancreatic cancer less amenable to ICIs than other cancers, the most common mutations found in pancreatic cancer are mutations in the KRAS gene, which in itself downregulates MHC-I, further reducing the efficacy of this form of therapy [8]. This evidence concerns the gene KRAS and pancreatic neoplasm.